Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Chronic thromboembolic pulmonary hypertension as a cause of dyspnoea in an older patient with a complex history

C. M. Kähler
European Respiratory Review 2009 18: 170-173; DOI: 10.1183/09059180.00003409
C. M. Kähler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

A full diagnostic work-up for patients with pulmonary hypertension (PH) is vital. Classification and diagnosis of the underlying cause is important to ensure optimal management, but may be complicated by overlapping signs and symptoms. This case study describes how a full work-up identified chronic thromboembolic PH (CTEPH) as the cause of dyspnoea in a 68-yr-old male with a history of pulmonary embolism and an original diagnosis of chronic obstructive pulmonary disease. Key indicators included decreased tricuspid annular plane systolic excursion, increased Tei index and elevated systolic pulmonary artery pressure. Multi-slice spiral chest computed tomography and pulmonary angiography showed severe chronic thromboembolic pulmonary disease, both centrally and distally. Diffusing capacity of the lung for carbon monoxide was reduced and blood gas analysis revealed a wide alveolar–arterial oxygen pressure difference, which is typical of CTEPH. The patient was eligible for pulmonary endarterectomy according to established criteria. Residual PH after surgery was successfully managed with bosentan.

  • Chronic thromboembolic pulmonary hypertension
  • dyspnoea
  • pulmonary hypertension

A 64-yr-old male first presented in 2003 at a local chest hospital with exertional dyspnoea, following a pulmonary embolism in 2002 and a history of smoking. At that time, a computed tomography (CT) scan revealed pulmonary embolism mainly in the left lower lobe; transthoracic echocardiography showed a slightly reduced left ventricular ejection fraction (EF) and elevated pulmonary arterial pressure (Ppa) (table 1⇓). He was hypoxic and hyperventilating, with low oxygen saturation. The patient was diagnosed with chronic obstructive pulmonary disease with hypoxaemia, and discharged; congestive heart failure was attributed to the low EF and the prior history of pulmonary embolism. Acenocoumarol, ramipril, carvedilol, oxygen and salbutamol were started. In 2007, he presented again at another local hospital with worsening dyspnoea; investigations showed increased Ppa, with similar EF and lung function to those at the first assessment (table 1⇓).

View this table:
  • View inline
  • View popup
Table. 1—

Initial and secondary assessment prior to referral to specialist unit

The patient was subsequently reinvestigated by a specialist pneumology unit. Transthoracic echocardiography revealed decreased tricuspid annular plane systolic excursion (TAPSE; 1.4 cm) with increased Tei index (1.61) and increased right atrial and ventricular dimensions, with estimated systolic Ppa of 70 mmHg (fig. 1⇓). At this stage, forced vital capacity was 90% predicted, forced expiratory volume in 1 s was 76% pred (a ratio of 69%) and peak expiratory flow was 70% pred. Lung function tests and CT excluded emphysema, with normal total lung capacity and residual volume, and no hyperinflation. The patient's 6-min walk distance (6MWD) was 384 m. However, the diffusing capacity of the lung for carbon monoxide was reduced (59%), as is the case in ∼20% of patients with idiopathic pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (CTEPH) [1, 2]. Multi-slice spiral chest CT and pulmonary angiography showed severe chronic thromboembolic pulmonary disease, both centrally and distally (fig. 2⇓). Doppler ultrasound revealed thrombosis of the vena poplitea up to the vena saphena magna on the left. Other investigations, including autoimmunity, sleep apnoea and HIV tests, were negative, although there was slight congestive hepatopathy. The patient was still hypoxic (arterial oxygen tension 56.4 mmHg) and hyperventilating (arterial carbon dioxide tension 30.2 mmHg), with low oxygen saturation (89%) and blood pH of 7.41. Blood gas analysis revealed a wide alveolar–arterial oxygen tension difference of 45.2 mmHg, which is typical for patients with CTEPH [3]. Diagnosis was supported by right heart catheterisation (table 2⇓).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Echocardiography image obtained during investigation by the specialist pneumology unit.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

a) Multi-slice spiral chest computed tomography scan and b) pulmonary arterial angiography at diagnosis of chronic thromboembolic pulmonary hypertension.

View this table:
  • View inline
  • View popup
Table. 2—

Right heart catheterisation at diagnosis of chronic thromboembolic pulmonary hypertension

The patient met the established criteria for pulmonary endarterectomy [4], including mean Ppa ≥25 mmHg, ≥3 months of effective oral anticoagulation, evidence of surgically accessible thrombi, a beneficial relationship between pulmonary vascular resistance (PVR) and the anticipated thrombus mass, no comorbidities and no severe reduction in lung function. At 1,200 dyn·s·cm−5, PVR was slightly higher than optimal (recommended <1,000 dyn·s·cm−5). The surgery was successful, and therapies including phenprocoumon, carvedilol, furosemide and salbutamol were started. Following surgery, N-terminal pro-brain natriuretic peptide concentrations declined from ∼5,000 to 1,000 ng·L−1, and 6MWD increased to 479 m, with an improvement in World Health Organization functional class (from III to II).

However, although the surgery reduced mean Ppa (from 61 to 44 mmHg), it was still higher than that of the normal population, as was PVR (reduced from 1,200 to 514 dyn·s·cm−5). Similarly, the Tei index, although reduced from 1.61 to 0.67, was not within the normal range (≤0.4), and TAPSE was still abnormal (≤2 cm), having changed little from 1.4 to 1.3 cm. This indicated that, despite the surgery, there was residual pulmonary hypertension (PH) (fig. 3⇓). To decrease the pulmonary pressure further, treatment with bosentan was initiated on a compassionate use basis and titrated to a final dose of 125 mg b.i.d. An increase in TAPSE (from 1.3 to 1.8 cm; approaching normal) and a decrease in Tei index (from 0.67 to 0.5; approaching normal) were observed following bosentan treatment. There was also a further improvement in 6MWD to 517 m. No further invasive assessments of haemodynamics were performed.

Fig. 3—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3—

a) Lung perfusion (seated patient) and b) high-resolution computed tomography scans obtained after pulmonary endarterectomy.

DISCUSSION

This case emphasises the importance of a full diagnostic work-up for patients with PH. Classification and diagnosis of the underlying cause of PH [5] is important, in order to ensure optimal management, but may be complicated by overlapping signs and symptoms. While dyspnoea is a common clinical finding in PH, it is nonspecific; therefore, a correct diagnosis of patients presenting with breathlessness relies on a full diagnostic work-up. Echocardiography is a useful noninvasive technique in this respect, allowing estimation of baseline and follow-up Ppa, tricuspid regurgitation, and atrial and ventricular size and function. However, the correlation between calculated Ppa by echocardiography and that measured by right heart catheterisation is reported to be poor [6, 7]. TAPSE and Tei index are useful parameters of right ventricular function in pulmonary arterial hypertension (PAH) and assessment of these may be more accurate than echocardiography-calculated Ppa alone [8]. In addition, TAPSE and Tei index are predictors of survival [9, 10] and may, therefore, be more useful for assessing treatment responses than calculated Ppa alone.

The occurrence of CTEPH after a diagnosis of acute pulmonary embolism, although rare, is more common than previously thought, being estimated at 3.8% of all patients surviving an episode of symptomatic idiopathic pulmonary embolism within 2 yrs [11]. Depending on established eligibility criteria, pulmonary endarterectomy is the preferred approach for CTEPH patients, and may restore haemodynamics in 80% of cases [4]. However, as illustrated here, surgery does not always correct the PH; in a recent UK study, 35% of 198 patients had mean Ppa >25 mmHg and PVR >240 dyn·s·cm−5 after surgery [12]. Residual PH is the most important determinant of post-endarterectomy outcome, being associated with decreased survival [8]. In the UK study, patients who survived to 3 months after surgery, but had persistent PH, had a 3-yr survival of 94% [12]. In such cases of persistent PH, management options are currently limited; in a UK cohort, 18% of patients with persistent disease already received PAH-modifying therapies [12].

In this case study, the post-surgical residual PH was successfully treated with bosentan. Bosentan has previously shown promise for CTEPH patients, including those considered unsuitable for surgery and cases that have residual PH after surgery [13–16]. The response of the current patient also suggests that bosentan may be of use for PH that persists despite surgery.

Conclusions

A full diagnostic work-up is required for patients with PH. Of those with CTEPH, candidates for pulmonary endarterectomy should be assessed against current eligibility criteria. The optimal management of inoperable cases of CTEPH is under evaluation and there are limited data describing the treatment of residual PH after surgery; however, there may be beneficial effects of novel targeted therapies, and further research is needed.

Statement of interest

C.M. Kähler has received honoraria for speaking or serving on advisory boards from Actelion, Pfizer, Bayer Schering, Encysive and AOP. The author is further supported by unrestricted research grants from Actelion, Encysive and AOP, and has received funds from Actelion, Pfizer, Bayer Schering, Encysive and AOP for members of staff and received consultancy fees from Actelion. C.M. Kähler has acted as an expert witness on the subject.

Provenance

Publication of this peer‐reviewed article was supported by Actelion Pharmaceuticals Ltd, Switzerland (unrestricted grant, European Respiratory Review issue 113).

Acknowledgments

The author would like to thank Elements Communications Ltd (Westerham, UK) for providing medical writing assistance supported by Actelion Pharmaceuticals Ltd (Allschwil, Switzerland).

  • Received June 1, 2009.
  • Accepted June 12, 2009.
  • © ERSJ Ltd

References

  1. ↵
    Burke CM, Glanville AR, Morris AJ, et al. Pulmonary function in advanced pulmonary hypertension. Thorax 1987; 42: 131–135.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Steenhuis LH, Groen HJ, Koëter GH, et al. Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension. Eur Respir J 2000; 16: 276–281.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Oswald-Mammosser M, Albert RK, Weitzenblum E, et al. AaDO2 as a predictor of pulmonary hypertension resulting from pulmonary emboli. Cor Vasa 1991; 33: 235–243.
    OpenUrlPubMed
  4. ↵
    Lang IM, Klepetko W. Chronic thromboembolic pulmonary hypertension: an updated review. Curr Opin Cardiol 2008; 23: 555–559.
    OpenUrlCrossRefPubMed
  5. ↵
    Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. S 5S–12S.
    OpenUrlCrossRefPubMed
  6. ↵
    Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S–47S.
    OpenUrlCrossRefPubMed
  7. ↵
    Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615–621.
    OpenUrlCrossRefPubMed
  8. ↵
    Vonk MC, Sander MH, van den Hoogen FH, et al. Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. Eur J Echocardiogr 2007; 8: 317–321.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Yeo TC, Dujardin KS, Tei C, et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81: 1157–1161.
    OpenUrlCrossRefPubMed
  10. ↵
    Ghio S, Klersy C, Magrini G, et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2008; [Epub ahead of print PMID: 19070379]
  11. ↵
    Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257–2264.
    OpenUrlCrossRefPubMed
  12. ↵
    Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177: 1122–1127.
    OpenUrlCrossRefPubMed
  13. ↵
    Mellemkjaer S, Ilkjaer LB, Klaaborg KE, et al. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Ten years experience in Denmark. Scand Cardiovasc J 2006; 40: 49–53.
    OpenUrlCrossRefPubMed
  14. Vassallo FG, Kodric M, Scarduelli C, et al. Bosentan for patients with chronic thromboembolic pulmonary hypertension. Eur J Intern Med 2009; 20: 24–29.
    OpenUrlCrossRefPubMed
  15. Jaïs X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in inoperable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 2127–2134.
    OpenUrlCrossRefPubMed
  16. ↵
    Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006; 28: 138–143.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 18 Issue 113 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Chronic thromboembolic pulmonary hypertension as a cause of dyspnoea in an older patient with a complex history
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Chronic thromboembolic pulmonary hypertension as a cause of dyspnoea in an older patient with a complex history
C. M. Kähler
European Respiratory Review Sep 2009, 18 (113) 170-173; DOI: 10.1183/09059180.00003409

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Chronic thromboembolic pulmonary hypertension as a cause of dyspnoea in an older patient with a complex history
C. M. Kähler
European Respiratory Review Sep 2009, 18 (113) 170-173; DOI: 10.1183/09059180.00003409
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • DISCUSSION
    • Statement of interest
    • Provenance
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Retrosternal and pleural “bridging” fibrosis mimicking malignancy in a patient exposed to asbestos
  • Organising pneumonia can be the inaugural manifestation in connective tissue diseases, including Sjögren's syndrome
  • Disseminated multiorgan MDR-TB resistant to virtually all first-line drugs
Show more Case Reports

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society